NCT03781323View on ClinicalTrials.gov

Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 3, 2019

Primary Completion Date

June 1, 2022

Study Completion Date

June 1, 2027

Conditions
Advanced Rectal Cancer
Interventions
DRUG

FOLFOX

"Patients treated on protocol will be treated with modified FOLFOX. Patients will receive 10 cycles of FOLFOX, administered every other week. FOLFOX will be given on day 1 of each cycle.~Patients will receive oxaliplatin 85 mg/m² IV over 120 minutes, leucovorin 400 mg/m² IV over 120 minutes, 5-FU 400 mg/m² IVP followed by 5-FU 2400 mg/m² infuse over 46 hours."

Trial Locations (2)

14642

University of Rochester, James P. Wilmot Cancer Center, Rochester

University of Rochester, Rochester

All Listed Sponsors
lead

University of Rochester

OTHER

NCT03781323 - Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer | Biotech Hunter | Biotech Hunter